龙金通淋胶囊治疗慢性前列腺炎/慢性骨盆疼痛综合征的初步研究

Preliminary Experience in Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome with Longjintonglin Capsule

目的:探讨龙金通淋胶囊治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS,III型前列腺炎)的疗效。方法:选择符合美国国立卫生研究院(NIH)诊断标准的III型前列腺炎患者136例,其中IIIA型84例,IIIB型52例。口服龙金通淋胶囊,3粒/次,3次/d,疗程3个月。以NIH-慢性前列腺炎症状指数(NIH-CPSI)和前列腺按摩液(EPS)白细胞计数为疗效指标,进行治疗前后疗效比较。结果:完成治疗的131例患者(IIIA型81例,IIIB型50例)中,NIH-CPSI总评分治疗前后分别为(24.8±5.6)分和(13.3±6.8)分(P<0.01),平均降低11.5分;症状评分治疗前后分别为(15.4±4.3)分和(8.7±3.9)分(P<0.01),平均降低6.7分;生活质量评分治疗前后分别为(9.4±3.7)分和(4.6±2.7)分(P<0.01),平均降低4.8分。IIIA型患者EPS中白细胞计数治疗前后分别为(21.7±14.5)个/HP和(8.8±12.6)个/HP。治愈者24例(18.3%),显效者41例(31.3%),有效者40例(30.5%),无效26例(19.8%)。总显效率49.6%,总有效率80.1%。未见肝肾功能异常及不良事件发生。结论:龙金通淋胶囊治疗慢性非细菌性前列腺炎安全、有效,无明显不良反应。

Objective： To explore the effectiveness of Longjintonglin capsule in treatment of chronic prostatitis/chronic pelvic pain syndrome（CP/CPPS）. Methods： One hundred and thirty-six patients accorded with the demands of chronic prostatitis type Ⅲ of National Institute of Health（ NIH）, among them there were 84 cases of chronic prostatitis type ⅢA and 52 cases of type ⅢB. All of the patients accepted oral Longintonglin capsule for 3 tablets ,3 times per day, for 3 months. NIH- chronic prostatitis symptom index（ NIHCPSI） and counting leukocytes in expressed prostatic secretions （EPS） were used as target to evaluate the effectiveness. Results： One hundred and thirty-one cases accomplished treatment, in which there were 81 cases of type ⅢA, and 50 cases of type ⅢB. Overall scores of NIH-CPSI before and after treatment were （24.8 ± 5.6 ） and （ 13.3 ± 6.8 ） points respectively, which dropped significandy （ average 11.5 points）, （ P 〈 0.01 ）. The symptom scores before and after treatment were （ 15.4 ± 4.3 ） and （ 8.7 ± 3.9 ） respectively, which also decreased significantly （ average 6.7 points）, （ P 〈 0.01 ）. The scores for quality of life before and after treatment were（9.4 ± 3.7 ） and （4.6 ± 2.7 ） respectively, which dropped significant （ average 4.8 points ） （ P 〈 0.01 ）. The leukocytes counts before and after treatment in patients with CP/CPPs type ⅢA were （21.7 ± 14.5 ）/HP and （8.8 ± 12.6）/HP, respectively. Twenty-four cases（ 18.3% ） got cured, 41 cases （31.3%） notable effect, 40 cases （30.5%） some effect, 26 cases （ 19.8% ） no effect, and total effective rate was 80.1%. No apparent side effect was observed in all patients accepted treatment, especially for their kidney and hepatic function. Conclusion ： Longintonglin capsule was a safe and effective medicine in treatment of CP/CPPS without significant side effect.